Aspirin in Type 2 Diabetes: A survey of prescribing habits and Investigation of effects on Inflammation, Oxidative stress, Insulin Resistance and Endothelial Function.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes（JPAD）Trial

  2011cited by this paper
• Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.

  2011cited by this paper
• Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects.

  2011cited by this paper
• High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial

  2011cited by this paper
• Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.

  2010cited by this paper
• Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors

  2010cited by this paper
• Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

  2010influential reference
• Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes

  2010cited by this paper
• An update on the role of markers of inflammation in atherosclerosis.

  2010cited by this paper
• Oxidative stress, nitric oxide, and diabetes.

  2010cited by this paper
• Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes

  2010cited by this paper
• Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events

  2010cited by this paper
• A pilot double‐blind randomised placebo‐controlled trial of the effects of fixed‐dose combination therapy (‘polypill’) on cardiovascular risk factors

  2010cited by this paper
• Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity

  2009cited by this paper
• Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As

  2009cited by this paper
• Short report: suboptimal diabetes care in high‐risk diabetic patients attending a specialist retina clinic

  2009cited by this paper
• Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

  2009cited by this paper
• Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

  2009cited by this paper
• A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.

  2009cited by this paper
• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

  2009influential reference
• Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

  2008cited by this paper
• Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

  2008cited by this paper
• ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

  2008cited by this paper
• ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

  2008cited by this paper
• Obesity and diabetes in the developing world--a growing challenge.

  2007cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

  2007cited by this paper
• A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study.

  2007cited by this paper
• Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

  2007cited by this paper
• Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.

  2007cited by this paper
• SUPPLEMENTARY ONLINE MATERIAL FOR: THE SPREAD OF OBESITY IN A LARGE SOCIAL NETWORK OVER 32 YEARS

  2007cited by this paper
• Review: Aspirin and diabetes

  2006cited by this paper
• Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study.

  2006cited by this paper
• Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women's Health Study: A Randomized Controlled Trial

  2006cited by this paper
• Contour analysis of the photoplethysmographic pulse measured at the finger

  2006influential reference
• Dose- and time-dependent antiplatelet effects of aspirin

  2006cited by this paper
• Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

  2006cited by this paper
• The Metabolic Syndrome: Time for a Critical Appraisal

  2006cited by this paper
• A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women

  2006cited by this paper
• C-Reactive Protein, Interleukin-6, and Soluble Adhesion Molecules as Predictors of Progressive Peripheral Atherosclerosis in the General Population: Edinburgh Artery Study

  2005cited by this paper
• The influence of type 2 diabetes on fibrin structure and function

  2005cited by this paper
• Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

  2005cited by this paper
• Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey.

  2005cited by this paper
• Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany

  2005cited by this paper
• Complement C3 and C-reactive protein levels in patients with stable coronary artery disease

  2005cited by this paper
• The metabolic syndrome: time for a critical appraisal

  2005cited by this paper
• Treadmill exercise in claudicants on aspirin results in improved antioxidant status but only minimal platelet activation

  2005cited by this paper
• The metabolic syndrome: a global public health problem and a new definition.

  2005cited by this paper
• Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin

  2005cited by this paper
• Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma.

  2005cited by this paper
• Glutathione levels in patients with erectile dysfunction, with or without diabetes mellitus.

  2005cited by this paper
• Prevalence of Patients with Type 2 Diabetes Mellitus Reaching the American Diabetes Association’s Target Guidelines in a University Primary Care Setting

  2004cited by this paper
• Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress.

  2004cited by this paper
• Changing aspirin use in patients with Type 2 diabetes in the UKPDS

  2004cited by this paper
• Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes.

  2004cited by this paper
• Increase in intranuclear nuclear factor κB and decrease in inhibitor κB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect

  2004cited by this paper
• Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

  2004cited by this paper
• Use and abuse of HOMA modeling.

  2004cited by this paper
• Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect.

  2004cited by this paper
• Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey.

  2004cited by this paper
• Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis.

  2004cited by this paper
• Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update.

  2004cited by this paper
• Acetylsalicylic Acid Inhibits Monocyte Adhesion to Endothelial Cells by an Antioxidative Mechanism

  2004cited by this paper
• Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III).

  2004cited by this paper
• Association of Type 2 Diabetes With Cyclooxygenase-Mediated Inflammation and Oxidative Stress in an Elderly Population

  2004cited by this paper
• Serial Urinary 11-Dehydrothromboxane B2, Aspirin Dose, and Vascular Events in Blacks After Recent Cerebral Infarction

  2004cited by this paper
• Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

  2004cited by this paper
• Aspirin for primary prevention of coronary heart disease.

  2004cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited

  2004cited by this paper
• Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action

  2004cited by this paper
• Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial.

  2004cited by this paper
• Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events

  2004cited by this paper
• Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?

  2004cited by this paper
• Aspirin rectifies calcium homeostasis, decreases reactive oxygen species, and increases NO production in high glucose-exposed human endothelial cells.

  2004cited by this paper
• C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women

  2003cited by this paper
• A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

  2003cited by this paper
• Aspirin inhibits human coronary artery endothelial cell proliferation by upregulation of p53.

  2003cited by this paper
• Effect of ibuprofen on cardioprotective effect of aspirin.

  2003cited by this paper
• Evidence that 5‐lipoxygenase and acetylated cyclooxygenase 2‐derived eicosanoids regulate leukocyte–endothelial adherence in response to aspirin

  2003cited by this paper
• European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)

  2003cited by this paper
• High incidence of clopidogrel‐associated gastrointestinal bleeding in patients with previous peptic ulcer disease

  2003cited by this paper
• The platelet in diabetes: focus on prevention of ischemic events.

  2003cited by this paper
• NF-kappa B activation in endothelial cells treated with oxidized high-density lipoprotein.

  2003cited by this paper
• Hyperglycemic crises in patients with diabetes mellitus.

  2003cited by this paper
• Endothelial activation by angiotensin II through NFκB and p38 pathways: Involvement of NFκB‐inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin

  2003cited by this paper
• Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

  2003cited by this paper
• Inflammation, the metabolic syndrome and cardiovascular risk.

  2003cited by this paper
• Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO.

  2003cited by this paper
• Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential

  2003cited by this paper
• Heme oxygenase-1 induction may explain the antioxidant profile of aspirin.

  2003cited by this paper
• NF-κB activation in endothelial cells treated with oxidized high-density lipoprotein

  2003cited by this paper
• Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs

  2003cited by this paper
• Nitric oxide-releasing drugs.

  2003cited by this paper
• Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study

  2003cited by this paper
• Differential effect of aspirin on platelet aggregation in patients with coronary artery disease in relation with associated risk factors.

  2003cited by this paper
• Determination of age-related increases in large artery stiffness by digital pulse contour analysis.

  2002cited by this paper
• Prevention of Inflammation-Induced Endothelial Dysfunction: A Novel Vasculo-Protective Action of Aspirin

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate.

  2002cited by this paper
• Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events

  2002cited by this paper

• No citing papers are available for this paper.